The short answer
High-dose vitamin E warrants caution with dabigatran etexilate, but the amount by which it changes bleeding risk with this exact medicine is not established. Food sources and concentrated supplements are different exposures. Review the total dose before adding vitamin E rather than relying on a timing gap.
What this answer covers
Oral vitamin E supplements with adult oral dabigatran etexilate. Food intake, natural/synthetic alpha-tocopherol and other vitamin E forms are not assigned identical risks.
- Supplement or preparation
- Vitamin E
- Medication ingredient
- dabigatran etexilate
Why are high doses a concern?
NIH describes effects of high-dose vitamin E on platelet aggregation and vitamin K-dependent clotting. These mechanisms support caution with anticoagulants. Dabigatran etexilate is the swallowed prodrug. The body converts it to dabigatran, which directly inhibits thrombin. Vitamin K-related observations in warfarin treatment do not by themselves show that vitamin E changes this medicine’s blood concentration.
What does the human evidence establish?
A small randomized trial in 21 warfarin-treated patients found no significant INR change with vitamin E. It was too small to exclude uncommon bleeding and did not study a direct oral anticoagulant. NIH also notes that the supplemental amount needed for clinically important anticoagulant effects is uncertain; a published dose estimate is not a guaranteed safe cutoff.
How should the supplement label be reviewed?
Count vitamin E from standalone products and multivitamins, noting whether the label uses milligrams or international units and which form it contains. Normal food intake is not equivalent to taking a concentrated high-dose supplement. Review the intended benefit, other antiplatelet medicines and any history of bleeding before increasing the dose.
Can spacing the doses solve the problem?
No validated hourly separation schedule has been established for vitamin E and dabigatran etexilate. The issue is possible effects on clotting, not a demonstrated same-time absorption interaction. Do not adjust the anticoagulant dose yourself. Seek advice for unusual bleeding and urgent care for severe or persistent bleeding while the full medication list is reviewed.
Evidence and practical considerations
Side effects & toxicity
High-dose vitamin E warrants caution with dabigatran etexilate, but the amount by which it changes bleeding risk with this exact medicine is not established. Food sources and concentrated supplements are different exposures. Review the total dose before adding vitamin E rather than relying on a timing gap.
- Exact scope
- Oral vitamin E supplements with adult oral dabigatran etexilate. Food intake, natural/synthetic alpha-tocopherol and other vitamin E forms are not assigned identical risks. with adult oral dabigatran etexilate mesylate capsules; active dabigatran produced after absorption
- Medication form and route
- adult oral dabigatran etexilate mesylate capsules; active dabigatran produced after absorption
- Timing or duration
- Concurrent oral use. Source-specific durations are recorded in the evidence entries; no unstudied duration threshold or separation schedule is inferred.
What remains uncertain
- Class-level safety guidance and indirect small warfarin trial. No exact-pair event estimate, validated safe vitamin E threshold, increased vitamin requirement or protective dose-spacing rule.
Factors that may matter: Exact supplement preparation, dose and additional ingredients; Kidney function, age, bleeding history and other antiplatelet or anticoagulant medicines; Current medication formulation and recent supplement start or stop.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving oral dabigatran etexilate capsules.
P-gp induction reduces active dabigatran exposure. P-gp inhibition and impaired renal function increase exposure. Capsules must be swallowed intact. RE-LY trough concentrations were not appreciably changed by concomitant PPIs or H2 blockers.
How this applies: Establishes the exact medicine’s mechanism, baseline bleeding precautions and formulation/transport limitations; it does not establish this supplement-specific interaction. Exact scope: Oral vitamin E supplements with adult oral dabigatran etexilate. Food intake, natural/synthetic alpha-tocopherol and other vitamin E forms are not assigned identical risks.
Named medicine dose adjustments cannot be extrapolated to untested herbs. Label silence about a supplement does not prove compatibility. Capsule results must not be generalized to every formulation.
Source 2: government clinical reference
ods.od.nih.gov · Source check Sep 10, 2026
Population: People using vitamin E supplements with anticoagulant or antiplatelet medicines.
The reference describes possible increased bleeding, especially when vitamin K intake is low, while stating that the clinically important amount is uncertain.
How this applies: Applied only as indirect context; the study or guidance did not establish an interaction with this exact direct oral anticoagulant. It is interpreted only alongside the current dabigatran etexilate label; any source using warfarin or no anticoagulant is indirect for this pair. Exact scope: Oral vitamin E supplements with adult oral dabigatran etexilate. Food intake, natural/synthetic alpha-tocopherol and other vitamin E forms are not assigned identical risks.
Guidance and evidence synthesis, not an exact-pair dose-finding trial. The suggested dose range must not be treated as a verified safe threshold.
Source 3: peer-reviewed original research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 21 people taking chronic warfarin randomized to vitamin E or placebo.
No significant INR change occurred in the vitamin E group.
How this applies: Applied only as indirect context; the study or guidance did not establish an interaction with this exact direct oral anticoagulant. It is interpreted only alongside the current dabigatran etexilate label; any source using warfarin or no anticoagulant is indirect for this pair. Exact scope: Oral vitamin E supplements with adult oral dabigatran etexilate. Food intake, natural/synthetic alpha-tocopherol and other vitamin E forms are not assigned identical risks.
Small trial; the available abstract cannot establish a dose threshold, bleeding risk or safety for all vitamin E products.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current labels and targeted original sources assessed; all current available claims adjudicated and consumer article prepared. Uncertainty and indirect evidence retained. Clinical sign-off not recorded. | |
| Research summary published |
Article revision: fcc47d9433bb1260
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.